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Abstract 
A fundamental property of infectious agents is their particulate nature: infectivity arises from independently-acting 
particles rather than as a result of collective action. Assemblies of the protein tau can exhibit seeding behaviour, 
potentially underlying the apparent spread of tau aggregation in many neurodegenerative diseases. Here we ask 
whether tau assemblies share with classical pathogens the characteristic of particulate behaviour. We used organo-
typic hippocampal slice cultures from P301S tau transgenic mice in order to precisely control the concentration of 
extracellular tau assemblies in neural tissue. Whilst untreated slices displayed no overt signs of pathology, exposure 
to recombinant tau assemblies could result in the formation of intraneuronal, hyperphosphorylated tau structures. 
However, seeding ability of tau assemblies did not titrate in a one-hit manner in neural tissue. The results suggest that 
seeding behaviour of tau arises at high concentrations, with implications for the interpretation of high-dose intracra-
nial challenge experiments and the possible contribution of seeded aggregation to human disease.
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Introduction
Neurodegenerative diseases are typified by the accu-
mulation of specific proteins into fibrillar assemblies. 
In around twenty distinct neurodegenerative diseases, 
including the most common, Alzheimer’s disease, the 
protein tau forms hyperphosphorylated, filamentous 
inclusions within the cytoplasm of neurons. Tau pathol-
ogy can be a direct cause of neurodegeneration. For 
instance, human genetic studies reveal that around 50 
distinct mutations in MAPT, the gene that encodes tau, 
cause inherited forms of dementia with evidence of tau 
filaments [1]. The origin of tau assemblies in the human 
brain remains uncertain. Cell-autonomous processes may 
lead to the spontaneous nucleation of oligomeric forms 
of tau within the cytoplasm of neurons. Some of these 
assemblies adopt filamentous conformations that are able 
to undergo extension by the addition of tau monomers 
to the filament ends. Over the past decade it has been 
postulated that, in addition to these cell-autonomous 
mechanisms, tau pathology may occur through a spread-
ing or ‘prion-like’ mechanism [2]. Several lines of evi-
dence demonstrate that assemblies of tau can be taken up 
into cells, whereupon they seed the conversion of native 
tau to the assembled state. Addition of tau assemblies 
to the exterior of cells, or the injection of tau assemblies 
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into the brains of tau-transgenic and wildtype mice, can 
induce intracellular tau assembly in the recipient [3–6].
Population cross-sectional studies demonstrate that the 
appearance of tau pathology follows a predictable pat-
tern over time and space in the human brain, potentially 
indicating spreading via a prion-like mechanism. Immu-
noreactivity to antibodies such as AT8, which detects 
tau that is phosphorylated at positions S202 and T205 
[7], progresses in a manner that can be systematically 
categorised into stages according to anatomical distri-
bution (Braak stages 0–VI) [8, 9]. In young adults, some 
AT8 immunoreactivity is observed in the vast majority 
of brains by the third decade of life. However, it is gener-
ally confined to neurons within the locus coeruleus (LC) 
in the brainstem (Braak pretangle stages 0 a–c and 1a,b). 
Subsequently, AT8 staining is observed in the entorhinal 
cortex (EC) and hippocampus (HC) (Braak stages I–II). 
Later stages are characterised by progressive dissemi-
nation and increasing density of staining in neocortical 
regions (Braak stages III–VI). These late stages are asso-
ciated with severe disease and the overall burden of tau 
pathology negatively correlates with cognitive function 
[10].
Though intracranial challenge experiments demon-
strate that seeded aggregation can in principle occur, 
they provide little insight as to whether physiological 
concentrations of extracellular tau species might support 
prion-like activity. The concentration of tau in wildtype 
mouse interstitial fluid (ISF) is around 50 ng/ml total tau 
(equivalent to ~ 1  nM tau monomer). Wildtype mouse 
ISF levels typically exceed cerebrospinal fluid (CSF) tau 
levels by around  tenfold [11]. In humans between ages 
21–50 years, CSF total tau is below 300 pg/ml increasing 
to 500 pg/ml over age 70 [12]—approximately 7–12 pM if 
considering the average mass of full length tau isoforms. 
Levels are increased  2–threefold in Alzheimer’s disease 
[13]. If a similar relationship between ISF and CSF tau 
concentration exists in humans as in mice, ISF tau lev-
els are likely in the order of 100 pM, rising to 300 pM in 
Alzheimer’s disease. Intracranial injection experiments 
typically supply tau in the high micromolar range. Even 
if this were distributed broadly across the brain, micro-
molar concentrations would be exceeded and local con-
centration at the injection site may plausibly be 100-fold 
greater. Thus, intracranial injection experiments likely 
exceed physiological concentrations of extracellular tau 
by two to seven orders of magnitude.
For classical infectious agents, infectivity is related to 
dose by a “one-hit” relationship wherein the amount of 
infectivity decreases linearly upon dilution until end-
point [14]. This property is also evident in  PrPSc prions, 
though it is complicated by the presence of multiple 
aggregation states and the size distribution of particles 
[15]. The relationship between dose and prion-like activ-
ity for tau has not been established. It is therefore cur-
rently not possible to reconcile high-dose challenge 
experiments with the low concentrations of tau observed 
in the extracellular spaces of the brain. To address this, 
we developed a model of seeded tau aggregation in 
mouse organotypic hippocampal slice cultures, allowing 
direct control of the concentration of tau neurons were 
exposed to. Brain slice cultures have been used for over 
40 years [16], though developments in recent years have 
rendered them increasingly relevant for the study of neu-
rodegenerative diseases [17–21]. We prepared slices from 
transgenic mice expressing human tau bearing the P301S 
mutation [22], which is causative of familial fronto-
temporal dementia and displays accelerated fibrilisation 
compared to wildtype tau [23].
Using our system, we show that neurons within CA1 
are preferentially susceptible to seeded aggregation, dis-
playing intracellular hyperphosphorylated tau tangles. 
We find that seeding activity cannot be titrated down 
and only occurs at high concentrations of tau assem-
blies. The concentrations of tau assemblies required to 
initiate seeding in this model exceed reported physiologi-
cal ranges of ISF and CSF tau. Our results imply that a 
model of tau spread via seeded aggregation requires 
these concentrations to be locally exceeded or requires 
other mechanisms not captured here to facilitate seeded 
aggregation.
Results
Sagittal hippocampal slices of ~ 300  µm thickness were 
prepared from homozygous P301S tau-transgenic mice at 
age 7 d, and cultured at the air–liquid interface on cul-
ture support membranes (Fig.  1a). Hippocampal struc-
tures are well developed at this age, yet the tissue exhibits 
plasticity that aids recovery from the slicing procedure 
[24]. We stained OHSCs with antibodies against mark-
ers of the major cell types of the brain: neurons (Map2), 
microglia (Iba1) and astrocytes (Gfap) (Fig.  1b). Similar 
to previous studies [20], neurons were found to maintain 
extensive arborisation with evidence of intact neuronal 
tracts. Microglia were observed with normal morphol-
ogy with extensive processes, similar to quiescent cells in 
whole brains [25]. Astrocytes were also well represented 
throughout the cultures. Immunostaining for P301S tau 
revealed widespread expression in all regions of the hip-
pocampus (Fig.  1c). After 5  weeks in culture no overt 
signs of tau pathology were apparent, as visualised by 
staining with AT8 (Fig.  1d). These results demonstrate 
that hippocampal architecture and cell types from P301S 
tau transgenic mice are maintained through the slicing 
and culture process. Importantly, they demonstrate that 
OHSCs from P301S tau transgenic mice do not undergo 
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detectable spontaneous aggregation over this time 
period.
To investigate the response of slice cultures to chal-
lenge with tau assemblies, we prepared tau from two 
independent sources. First, we expressed the 0N4R 
isoform of tau bearing the P301S mutation in E. coli. 
Recombinant protein was incubated with heparin and, 
following a lag period, was found to give a  fluorescent 
signal in the presence of thioflavin T, a dye whose fluo-
rescence increases upon binding to β-sheet rich amyloid 
Fig. 1 Organotypic hippocampal slice cultures (OHSCs) maintain cellular diversity and display no spontaneous tau pathology. a Schematic of the 
production of OHSCs. 300 µm thick sagittal slices are cut from brain hemispheres. The hippocampus is then dissected and cultured at the air–liquid 
interface on semi-permeable membranes with media supplied to the basal side of the membrane. b OHSCs from mice transgenic for P301S tau 
were fixed after 2 weeks in culture and stained for nuclei (DAPI), the neuronal marker Map2, the astrocyte marker Gfap, and the microglial marker 
Iba1. Scale bars, 50 µm. c OHSCs from P301S tau transgenic mice stain positive for human tau-specific antibody HT7 whereas OHSCs from WT mice 
do not. Scale bars, 250 µm and 25 µm. d OHSCs from P301S tau transgenic mice after 5 weeks in culture display only background levels of staining 
with the phospho-tau specific antibody AT8. Slices were stained with DAPI and Map2 as above and with pan-tau. Scale bars, 250 µm
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structures (Fig. 2a). Negative stain transmission electron 
microscopy revealed the presence of abundant filamen-
tous structures (Fig. 2b). Second, we prepared the sarko-
syl-insoluble (SI) fraction from aged P301S tau transgenic 
mice, a procedure that enriches insoluble tau species. 
Brain-derived assemblies were subjected to western blot, 
confirming the presence of hyperphosphorylated, insolu-
ble tau (Fig. 2c). The samples were quantified using a dot-
blot method using recombinant fibrillar tau as a standard 
(Additional file 1: Supplementary Fig. 1). Tau assemblies 
were added to HEK293 cells stably expressing 0N4R 
P301S tau-venus, a reporter cell line for seeded aggrega-
tion [26]. In this assay, transfection reagents are used to 
deliver tau assemblies into cells, whereupon tau-venus 
is observed to form puncta over 1–2 d. This aggrega-
tion was previously found to result in the accumulation 
of tau-venus in the sarkosyl-insoluble pellet [26]. In the 
present study, abundant venus-positive puncta were 
detected following challenge with recombinant fibrils or 
mouse brain derived tau (Fig. 2d). To investigate whether 
these seeded assemblies bore markers of tau hyperphos-
phorylation, we stained with the monoclonal antibody 
AT8 and AT100, which recognises tau phosphorylated at 
pT212 and pS214. These epitopes occur on tau filaments 
extracted from post-mortem tauopathy brains, including 
those from Alzheimer’s disease patients. We observed 
that challenge with recombinant tau assemblies resulted 
in colocalization between tau-venus puncta and AT8 or 
AT100 (Fig. 2e, f ). We therefore concluded that our tau 
preparations contained species able to induce bona fide 
seeded aggregation in recipient cells.
To test whether OHSCs support seeded aggregation, 
we treated slices at DIV7 with recombinant tau assem-
blies or mouse brain derived sarkosyl insoluble (SI) tau. 
Fig. 2 Characterisation of seed competent tau assemblies. a Time course of recombinant P301S tau assembly, monitored by Thioflavin T 
fluorescence. b Representative transmission electron microscopy image of heparin assembled P301S tau. c Aged P301S tau transgenic mouse brain 
homogenate was immunoblotted for human tau (HT7 antibody) to detect transgenic tau and for cyclophilin B which served as a loading control. 
Presence of sarkosyl insoluble (SI) tau was confirmed with the HT7 antibody and AT100 (tau phosphorylated at pT212, pT214). Lanes represent 
preparations from different mice which were subsequently pooled. d Representative images from HEK293 cells expressing P301S tau-venus 48 h 
after challenge with either recombinant P301S tau assemblies or mouse SI tau in the presence of LF2000. e, f Tau-venus aggregates observed 
following challenge with tau assemblies stain with AT8 and AT100 demonstrating that the induced tau aggregates are phosphorylated. Scale bars, 
20 µm
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Fig. 3 Challenging OHSCs with exogenous tau assemblies induces seeded tau aggregation. a Timeline of organotypic hippocampal slice culture 
preparation and treatment. OHSCs were prepared from P7 pups. After 7 days in vitro (DIV), tau assemblies were added to the media and incubated 
for 3 days. A complete media change was carried out at the end of the seeding period (pink). At other times (green) 50% media changes were 
performed twice weekly until fixation at 28 days in vitro (DIV). b OHSCs derived from P301S tau transgenic mice were challenged with either 
100 nM recombinant tau assemblies, 100 nM monomeric tau, 5 µL (~ 300 nM) of mouse brain origin sarkosyl insoluble (SI) tau or buffer only. WT 
OHSCs were challenged with 100 nM recombinant tau assemblies or buffer only. Scale bars, 50 µm. c Quantification of seeding levels in WT and 
P301S tau transgenic OHSCs, following addition of 100 nM recombinant tau assemblies or buffer only. d Levels of AT8 immunostaining following 
challenge of OHSCs with monomeric tau (Mono) or heparin assembled tau (Seed). e, f Levels of sarkosyl insoluble tau present in transgenic P301S 
(e) or WT (f) OHSCs with and without the addition of 100 nM recombinant tau assemblies. Data derived from Western blot, normalised to input 
levels of tau and loading control. g Levels of human tau (HT7) present in WT OHSCs after 3 days of exposure to 300 nM recombinant tau assemblies 
applied beneath the membrane. c and d, statistical significance determined by Kruskal–Wallis test by ranks and Dunn’s multiple comparisons test. 
e–g statistical significance determined by unpaired t-test. For panels c–f, data points represent individual fields of view from multiple slices derived 
from N = 3 mice per condition. ****P < 0.0001; **P < 0.01; *P < 0.05; ns, not significant)
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After three days a complete media change was performed 
to remove the tau, and the OHSCs were incubated for a 
further three weeks (Fig.  3a). Following treatment with 
tau assemblies, we observed pronounced AT8 stain-
ing, suggesting the presence of intracellular hyperphos-
phorylated tau structures (Fig.  3b, c). The addition of 
monomeric tau did not induce these same structures, 
indicating that the misfolded state of tau was responsible 
for seeded aggregation (Fig. 3b, d). Furthermore, addition 
of tau assemblies to OHSCs prepared from wildtype mice 
did not induce seeded aggregation suggesting that the 
transgenic P301S tau construct is responsible for the phe-
notype (Fig. 3b, c). The hyperphosphorylation of tau was 
accompanied by the accumulation of sarkosyl-insoluble 
species following seeding in P301S transgenic OHSCs 
but not in wildtype OHSCs (Fig. 3e, f ) (Additional file 1: 
Supplementary Fig. 2). Whilst the human transgenic tau 
is therefore required for seeding to occur, we cannot 
exclude the possibility that endogenous mouse tau also 
contributes to aggregates in the transgenic slices since 
the AT8 epitope is identical between human and mouse 
tau. To test whether exogenously applied tau could be 
found within the slices, recombinant tau assemblies were 
supplied to the culture media of wildtype slices, beneath 
the membrane, for a period of three days. After this time, 
we observed human tau present in the slices by western 
blot, indicating the transfer of tau assemblies from the 
media to the slice (Fig. 3g) (Additional file 1: Supplemen-
tary Fig. 2). Taken together, these data demonstrate that 
exogenously supplied tau assemblies are taken up into 
OHSCs and can induce the formation of hyperphospho-
rylated, insoluble tau species.
To further characterise the induced aggregates, we 
investigated the subcellular and regional location of tau 
lesions. We used recombinant tau assemblies to induce 
seeding owing to the high confidence that AT8-reactive 
aggregates result from seeded aggregation rather than 
the input tau. Within cell bodies, we observed large 
aggregates in peri-nuclear regions (Fig.  4a). Addition-
ally, numerous smaller tau puncta were found along the 
length of neurites. Puncta were interrupted by regions 
apparently devoid of hyperphosphorylated tau. In con-
trast, Map2 staining revealed the presence of intact neu-
rites, indicating that the punctate distribution of tau is 
not a consequence of neuronal fragmentation. They fur-
ther demonstrate that neurons are able to tolerate tau 
aggregation to a certain degree without gross loss of mor-
phology or overt toxicity. We compared levels of seeding 
between regions of the hippocampal slices. We observed 
the presence of AT8 positive structures in neurons within 
all subdivisions (Fig.  4b). However, AT8 reactivity was 
considerably greater within the CA1 region compared 
to CA2 and CA3. Approximately 80% of AT8-postitive 
structures were found in CA1, compared to ~ 10% in 
each of CA2 and CA3 (Fig.  4c). We examined levels of 
tau as a potential underlying cause of CA1 susceptibility 
but observed comparable expression levels across differ-
ent regions (Fig. 4d). In summary, these results demon-
strate that challenge of OHSCs with assemblies of tau 
induces the accumulation of pathology in neurites and 
cell bodies, predominantly in CA1 neurons, resulting in 
widespread accumulation of intracellular hyperphospho-
rylated tau structures.
To determine the time-dependence of this tau pathol-
ogy, we next performed a time course following the 
addition of seed. Slices were fixed at various time points 
following challenge with 100  nM recombinant assem-
blies or buffer only (Fig.  5a). As above, slices that were 
not exposed to tau assemblies developed no robust evi-
dence of hyperphosphorylated tau puncta. However, 
challenge with tau assemblies resulted in increasing lev-
els of bright AT8-positive structures over time, consist-
ent with seeded aggregation of intracellular pools of tau 
(Fig. 5b). At 1 week after challenge, isolated AT8 positive 
puncta were observed as well as diffuse AT8 staining. 
A week later, puncta became more numerous and a few 
large aggregates were observed. At 3  weeks after chal-
lenge with tau assemblies, AT8 staining was widespread 
with the presence of numerous aggregates that occupied 
entire cell bodies. This level of staining was maintained 
at approximately the same level between 3 and 4 weeks, 
suggesting that the induced aggregation is complete at 
3  weeks post-challenge in this system. This timepoint 
was therefore selected for all further experiments. Dur-
ing the first three weeks, AT8 staining followed an expo-
nential curve with a doubling time of just under a week 
(Fig.  5c). The size of AT8-positive structures was simi-
larly found to increase over time. Stained areas greater 
than 50 µm2, generally only present within cell bodies, 
were found to be largely absent at 1 week post-challenge, 
but subsequently increased in prevalence (Fig.  5d). This 
suggests that the amplification of aggregates within indi-
vidual neurons contributes to the overall increase in AT8 
signal. The results are therefore consistent with a model 
of growth of hyperphosphorylated tau structures via a 
process of templated aggregation following exposure to 
seed-competent tau assemblies.
The above results demonstrate that our OHSC model 
exhibits behaviour consistent with the prion-like spread 
of tau. However, the dose we used (100  nM monomer 
equivalent) represents a concentration in excess of ISF 
and CSF tau concentrations, which occupy the low 
nanomolar to picomolar region. We therefore investi-
gated the response of OHSCs to varying doses of exog-
enously supplied tau assemblies. Remarkably, we found 
that a reduction of seed concentration from 100 to 
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30 nM resulted in virtually no seeded aggregation being 
detectable within the slice at three weeks post-challenge 
(Fig. 6a). Whereas cell bodies reactive for AT8 could be 
observed when challenged with 100 nM tau assemblies, 
only very rare and small AT8-positive assemblies in neu-
rites were observed following challenge with 30 nM tau. 
Fig. 4 Seeded neurons localise to CA1 and display phospho-tau aggregates within intact nerve processes. a OHSCs were challenged with 100 nM 
recombinant tau assemblies to induce seeded aggregation. Hyperphosphorylated tau puncta can be observed along intact nerve processes 
(arrows) and within cell bodies. Scale bars, 25 µm. b Tiled image of representative OHSC challenged with 100 nM recombinant tau assemblies 
displays AT8 immunoreactivity predominantly in the CA1 subregion. Scale bars, 250 µm. c The distribution of seeded cells in hippocampal 
subregions was quantified by counting cells positive for AT8 aggregates. d Levels of tau, as quantified by immunofluorescence staining with 
pan-tau antibody, shows that CA1, CA2 and CA3 express similar levels of tau. Statistical significance for c and d determined by one-way ANOVA and 
Tukey’s post hoc multiple comparisons test (multiple fields imaged from N = 6 mice. ****P < 0.0001)
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Conversely, increasing exogenous tau concentration from 
100 to 300 nM increased the AT8-immunoreactive area 
by almost tenfold, consistent with a non-linear effect 
of tau concentration in this range (Fig.  6b). To exclude 
any effect of the culture membrane on the efficiency of 
tau uptake, we applied tau at the same concentrations 
Fig. 5 Seeded aggregation occurs over three weeks. a Schematic of OHSC treatment. 100 nM recombinant tau assemblies were added to the 
media as previous and left for 3 days (pink) followed by a complete media change. Subsequently 50% media changes were performed twice 
weekly (green) until fixation at 1, 2, 3 or 4 weeks post challenge. b Slices fixed at 1 week post challenge display diffuse AT8 staining. Slices fixed 
at 2 or 3 weeks demonstrate increasing levels of AT8 reactivity in cell bodies and neurites. OHSCs not challenged with exogenous tau assemblies 
exhibit only diffuse background levels of AT8 reactivity. Scale bars, 100 µm. c Percent AT8-positive area increases over time following challenge with 
recombinant tau assemblies. Statistical significance determined by Kruskal–Wallis Test by ranks and Dunn’s multiple comparisons test compared 
to 0 weeks post challenge unless indicated (multiple fields imaged from slices from N = 3 mice, per time point. *P < 0.05, ****P < 0.0001). Inset 
represents the same data from weeks 1–4 plotted on a logarithmic scale. Doubling time (Td) estimated from linear regression curve fitted to data 
up to 3 weeks. d AT8 positive puncta increase in size following challenge with 100 nM recombinant assemblies. Dotted line at 50 µm2 represents 
approximate lower size limit of cell body-occupying lesions. Statistical significance determined by Kruskal–Wallis Test by ranks and Dunn’s multiple 
comparisons test (multiple fields imaged from slices from N = 3 mice at each time point. ***P < 0.001)
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directly to the apical surface of the slices in a volume 
of 20  µl. Under both experimental set-ups we observed 
robust induction of seeding at 100 nM, but not at 30 nM 
(Fig.  6c). Thus, the local concentration of tau governs 
seeded aggregation and is independent of application 
route. The smaller volumes required for apical applica-
tion of tau permitted challenge with an extreme concen-
tration of supplied tau, at 1000 nM. Here we observed a 
plateauing of percent AT8-positive area and the presence 
of AT8 reactivity in almost all neurons (Additional file 1: 
Supplementary Fig.  3). These results demonstrate that 
tau seeding in OHSCs only occurs efficiently at concen-
trations above 100  nM of supplied assemblies, and pla-
teaus in the low micromolar range.
Independently acting infectious particles such as 
viruses retain infectivity upon dilution until they are 
diluted out at endpoint. They display one-hit dynam-
ics where the proportion of infected cells, P(I), can be 
described by the equation P(I) = 1 − e−m where m is the 
average number of infectious agents added per cell. To 
determine whether tau assemblies display these prop-
erties, we titrated tau assemblies onto HEK293 cells 
expressing P301S tau-venus. Here, where conditions have 
been optimised for sensitive detection of seeding, and 
tau assemblies are delivered directly to the cytoplasm 
with transfection reagents, we observe that seeding activ-
ity is proportional to dose and can be titrated down. 
The observed level of seeding closely follows a one-hit 
titration curve (Fig.  7a). Thus, tau assemblies have the 
Fig. 6 Tau seeding does not occur at low dose. a OHSCs challenged with 30 nM, 100 nM and 300 nM of recombinant tau assemblies or with buffer 
only, supplied into the media beneath the insert in a volume of 1 ml. Scale bars, 50 µm. b Quantification of AT8 immunoreactivity in OHSCs treated 
as above. c Quantification of seeding levels in P301S OHSCs, upon the addition of recombinant tau assemblies or buffer only to the apical surface of 
individual slices. Statistical significance determined by Kruskal–Wallis Test by ranks and Dunn’s multiple comparisons test (Slices from N = 6 mice per 
condition. ****P < 0.0001)
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intrinsic ability to act as independent particles when 
tested in reporter cell lines. This is in direct contrast to 
the results observed in OHSCs where seeding reduces 
much more rapidly as tau assemblies are diluted than 
would be expected under a single-hit model (Fig.  7b). 
One potential explanation for these differences is that 
clearance mechanisms in intact tissue inherently prevent 
single-particle activity. To test this, we titrated AAV1/2.
hSyn-GFP particles expressing GFP and measured the 
percent of Map2-positive neurons that were transduced. 
We observed that AAV1/2 behaved in a manner consist-
ent with one-hit dynamics (Fig. 7c). Thus, tau assemblies 
differ from classical infectious agents and do not titrate 
in a manner expected of independently acting particles 
in mouse neural tissue. Rather, in this system, seeding is 




Elucidating the mechanism of tau aggregation and its 
apparent spread through the brain is critical to the 
development of mechanism-based therapeutics. The 
‘prion-like’ model of tau spread posits that the transit of 
assembled tau species from affected to naïve cells pro-
motes the exponential spread of pathological tau over 
time within a diseased brain. In support of this model, 
extracellular fluids of tauopathy patients’ brains contain 
seed-competent tau species: CSF samples from both AD 
and Pick’s disease patients give rise to seeded aggregation 
in biosensor cell lines and biochemical detection assays 
[27–29]. Further evidence in support of the prion-like 
model comes from in vivo challenge experiments: intrac-
ranial injection of assembled tau can result in induced tau 
pathology in wildtype or tau-transgenic rodent brains. 
Understanding whether the behaviour of tau is con-
served between the high concentrations typically used in 
in vivo injection experiments, and the low levels present 
in the extracellular spaces of the brain, is important when 
assessing the possible contribution of seeded aggregation 
as a disease mechanism.
To investigate the dose–response of tau assemblies in 
neural tissue, we established an organotypic hippocampal 
slice culture system for studying seeded aggregation that, 
unlike whole animal studies, allows precise control of 
tau assembly concentration and exposure time. We pre-
pared recombinant tau assemblies with confirmed seed-
ing activity and applied these assemblies to OHSCs from 
P301S tau transgenic mice. We observed that tau pathol-
ogy in the OHSCs increased over a period of three weeks, 
at which point cell body-occupying, hyperphosphoryl-
ated tau lesions were observed. This was associated with 
the accumulation of tau in the sarkosyl insoluble fraction. 
No overt signs of cell death were observed, and neu-
rons bearing tau lesions with intact processes were evi-
dent. Seeded aggregation was dependent on transgenic 
human tau, since no seeded aggregation was observed 
in wildtype mouse OSHCs. While others have reported 
seeded aggregation of wildtype murine tau following 
challenge with human brain-origin tau assemblies [6], we 
consider it likely that the P301S tau assemblies preferen-
tially seed the homotypic P301S tau within the neurons. 
Fig. 7 Tau seeding does not conform to one-hit dynamics. a Levels of seeding in HEK293 cells expressing P301S tau-venus following titration of 
recombinant tau assemblies in the presence of Lipofectamine 2000 transfection reagent. Percent of cells seeded was determined by high content 
microscopy and expressed as percent maximum observed seeding. A one-hit curve was fitted using values outside the plateau. b Levels of seeded 
aggregation in P301S tau transgenic OHSCs treated with recombinant tau assemblies applied to the apical surface of OHSCs. Percent AT8 area was 
measured and expressed as percent of maximum seeding (raw data in Additional file 1: Supplementary Fig. 3). For illustration, a one-hit curve was 
extended from a data point below saturation. c Infection of P301S tau transgenic OHSCs with a titration of AAV1/2.hSyn-GFP, with a one-hit curve 
fitted using all data points (Slices from N = 3 mice per condition)
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Surprisingly, we found that tau seeding activity rapidly 
dropped away upon dilution in OHSCs. Dilution of tau 
assemblies to 30  nM or below prevented essentially all 
seeded aggregation. This concentration is long before 
end-point dilution of tau assemblies and represents a 
marked deviation from one-hit dynamics. In contrast, tau 
assemblies displayed one-hit dynamics when delivered 
directly to the cytoplasm in a HEK293 cell line modified 
to express P301S tau-venus.
Deviations from one-hit dynamics in virus infection 
can be caused by host cell factors that prevent infection 
at low viral dose, but become saturated at high viral dose 
[30, 31]. By analogy, we consider it likely that homeo-
static mechanisms act to prevent seeded aggregation of 
tau but become saturated by high tau concentrations. 
The nature of any such saturable barrier to seeding is not 
clear. One possibility is that phagocytic cells present in 
slices preclude observations of one-hit dynamics. How-
ever, AAV particles were found to titrate with one-hit 
dynamics in OHSCs, demonstrating one-hit dynamics 
can be observed in neurons in the presence of glia. A triv-
ial explanation of tau at low concentrations being unable 
to cross the culture support membrane was also ruled 
out by also applying tau to the apical side of the OHSCs. 
Here, we observed the same dynamics, with loss of seed-
ing activity at 30  nM. Other mechanisms are therefore 
implicated such as saturation of proteostatic mechanisms 
or saturation of cellular uptake pathways. Identification 
of these defences may provide a valuable route to under-
standing the homeostatic mechanisms which prevent the 
prion-like propagation of tau, and their potential deterio-
ration in disease.
Limits of this study
There are certain caveats and limitations of our model 
that require examination  before considering the results 
in the context of disease. First, the tau species present 
in the extracellular spaces of the brain are likely to dif-
fer from those used here. We have used heparin-assem-
bled recombinant filaments, which are known to differ 
in structure from brain-derived filaments [32]. Second, 
brain-origin fibrils have extensive post-translational 
modifications including hyperphosphorylation and pro-
teolytic truncation, which may alter activity compared 
to the full-length tau isoform used here that lacks phos-
phorylation. Though the effects that fibril structure 
and post-translational modifications have on biologi-
cal activity are poorly defined, we cannot exclude that 
brain-origin assemblies retain seeding potency at lower 
concentrations. Finally, we have used a transgenic ani-
mal that expresses P301S human tau as a model of tau 
pathology. Given that P301S is a pro-aggregant mutation 
that undergoes enhanced fibrilisation [23] compared to 
wildtype tau it would be expected that the transgenic tau 
would be more sensitive to seeded aggregation. However, 
there may be unexpected effects in wildtype systems not 
captured here. Additionally, the endogenous mouse tau 
may have further effects on the phenotype we observe in 
the P301S OHSCs. For instance, it has previously been 
shown that endogenous mouse tau can partially inhibit 
transgene aggregation [33]. Further research is there-
fore required to determine whether the loss of seeding 
potency at low concentrations is a general feature of tau 
assemblies in neural tissue.
Implications of the results
Notwithstanding the caveats above, our results suggest 
that healthy neural tissue is able to withstand the con-
centration of tau present in extracellular fluids without 
observable seeded aggregation. The effective threshold 
for seeding, measured here at around 100  nM, exceeds 
physiological ISF/CSF concentrations by several orders 
of magnitude. Thus, the results suggest that other mecha-
nisms are required in order for seeded aggregation to 
occur in the brain. For instance, uncontrolled neuronal 
cell death or release of tau into synaptic clefts may tran-
siently raise the local concentration of tau to high levels. 
Alternatively, the threshold for seeded tau aggregation 
may be altered in the degenerating brain, for instance 
through inflammation or other mechanisms. Finally, 
other modes of transmission within the brain that do not 
rely on naked pools of extracellular tau may circumvent 
the non-linear dose response observed here. Such mech-
anisms include tau spreading via tunnelling nanotubules 
and in extracellular vesicles [34, 35].
One of the main pieces of evidence in support of the 
‘prion-like’ hypothesis of tau spread in human disease is 
the induction of seeded aggregation in mouse neurons 
following intracranial injection of tau assemblies. These 
studies have been performed in multiple mouse models, 
with various ages of animal and with multiple sources of 
tau assemblies (Additional file 1: Supplementary Table 1). 
However, the doses injected are mostly in the tens of 
micromolar range, thus exceeding physiological ISF/
CSF tau concentrations by several orders of magnitude. 
Diffusion after injection is likely to reduce the effective 
concentration that neurons are exposed to, though for 
many of these experiments, levels are still likely to exceed 
micromolar concentrations even if diluted across the 
whole brain. The data we present here suggests that these 
experiments may not be simply extrapolated downwards 
to infer the behaviour of tau assemblies at low concentra-
tions. Rather, our results imply that seeding activity is an 
emergent property of high doses of tau assemblies when 
applied extracellularly to neural tissue.
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It is not usually clear from studies available in the 
literature if lower doses were attempted but failed to 
support seeded aggregation, or if higher doses were 
selected for other practical purposes. Potentially of 
interest in this regard is the study by Skachokova and 
colleagues who successfully induced seeding following 
injection of P301S tau transgenic mice with a 1000-fold 
concentrate of CSF from AD patients [36]. At 4–17 nM, 
these samples are still far in excess of human CSF tau 
concentrations. But, notably, these concentrations are 
below the threshold defined in our OHSC model, sig-
nifying different tau preparations may have different 
seeding thresholds, and indicating that micromolar 
concentrations of tau might not always be required to 
induce seeding in vivo.
Our results have further implications for reporter cell 
lines, which are widely used for the detection of seed-
competent tau assemblies [4, 26, 37]. These systems are 
optimised for the sensitive detection of seeds by using 
high expression levels of truncated or mutant tau, trans-
fection reagents to deliver seeds into the cytosol and sen-
sitive microscopy or FACS-based detection. Our results 
suggest that the dose–response of tau assemblies in a 
reporter line closely resembles one-hit dynamics. This 
is beneficial in the sense that the concentration of tau 
seeds in a sample can be determined irrespective of the 
dose applied. Indeed, the absence of seeding at low dose 
in neural settings implies that reporter cell lines may be 
necessary for detection of seeding activity in many sam-
ples. Conversely, our results suggest that caution must be 
applied when interpreting any seeding detected in these 
systems, since the absence of one-hit dynamics in neural 
tissue means that concentrations of tau assemblies that 
are active in reporter lines may have no activity in a more 
physiological setting.
Evidence of CA1 vulnerability
Our experiments demonstrated that neurons in CA1 
were particularly sensitive to seeded aggregation com-
pared to those in CA2 and CA3. Whilst injection of tau 
assemblies to the in vivo brain also demonstrates promi-
nent CA1 seeding, proximity to the injection site is the 
major determinant of seeding in animal studies, thereby 
confounding conclusions of regional susceptibility [3, 5, 
38]. We found that tau substrate levels were not impli-
cated in the phenotype, suggesting that other factors are 
responsible for the increased susceptibility. These results 
are potentially of interest in the study of selective vul-
nerability since it is well established that CA1 displays 
more pronounced AT8 reactivity in post-mortem human 
brains [9, 39, 40]. In humans, the advanced pathology 
in CA1 versus other HC regions could potentially be 
explained either by selective vulnerability of its neurons 
to aggregation, or by its upstream position in the cir-
cuitry of the HC, making it prone to earlier and more 
pronounced pathology under a spreading model. Our 
findings lend support to an underlying increased suscep-
tibility of CA1 neurons to pathology. OHSCs therefore 
provide a suitable platform for future studies to deter-
mine the biological basis of this susceptibility.
Conclusion
Our findings help define the prion-like characteristics 
of tau assemblies. Whilst intrinsic seeding activity of 
recombinant tau assemblies that titrate according to 
a one-hit dose–response can be detected in biosensor 
assays, this behaviour is lost in neural tissue. Our findings 
suggest that neural tissue possesses as yet unidentified 
homeostatic mechanisms that are capable of successfully 
preventing seeded aggregation. High levels of tau assem-




All animal work was licensed under the UK Animals (Sci-
entific Procedures) Act 1986 and approved by the Medi-
cal Research Council Animal Welfare and Ethical Review 
Body. P301S tau transgenic mice [22] that had been 
extensively backcrossed to C57BL/6 background were 
obtained from Dr Michel Goedert, MRC Laboratory of 
Molecular Biology, UK. Wildtype mice in this study refer 
to C57BL/6 mice. Male and female mice were used in the 
study and humanely sacrificed by cervical dislocation.
Recombinant tau production
The expression and purification of recombinant human 
0N4R tau bearing the P301S mutation from E. coli BL-21 
(DE3, Agilent Technologies) was performed as described 
previously (Goedert and Jakes, 1990) with small modi-
fications. Bacterial pellets were collected through cen-
trifugation (3300 g, 4 °C, 10 min) and then resuspended 
in 10  ml/L of culture with buffer A (50  mM MES pH 
6.5, 10 mM EDTA, 14 mM β-mercaptoethanol, 0.1 mM 
PMSF, 1 mM benzamidine, 1 × complete EDTA-free pro-
tease inhibitors). The resuspended bacteria were lysed on 
ice using a probe sonicator (approximately 60% ampli-
tude) and then boiled for 10  min at 95  °C to pellet the 
majority of proteins, while tau will remain in solution 
as a natively unfolded protein. Denatured proteins were 
pelleted through ultracentrifugation (100,000  g, 4  °C, 
50 min). The clarified supernatant containing monomeric 
tau P301S was then passed through a HiTrap CaptoS 
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(Cytiva) cation exchange column and the bound proteins 
were eluted through a 0–50% gradient elution with Buffer 
A containing 1  M NaCl. Eluted fractions were assessed 
through SDS-PAGE and total protein staining with 
Coomassie InstantBlue. Fractions of interest were con-
centrated using 10  kDa cut-off Amicon Ultra-4 concen-
trators (Merck Millipore) before loading on a Superdex 
200 10/300 GL (Cytiva) size exclusion chromatography 
column. The final tau P301S protein was stored in PBS 
containing 1  mM DTT. All the affinity purification and 
size exclusion chromatography steps were performed 
using the ÄKTA Pure system (Cytiva).
Recombinant tau aggregation
Tau monomer was added to aggregation buffer (20  μM 
Heparin, 60  μM P301S tau monomer, 1 × complete 
EDTA-free protease inhibitors, 2  µM DTT in PBS) and 
incubated at 37 °C for 3 days. The resulting P301S tau fil-
aments were sonicated for 15 s before long-term storage 
at − 80 °C.
ThioflavinT assay
Tau monomer was added to aggregation buffer, with 
10  µM sterile filtered ThioflavinT (ThT). Samples were 
loaded in triplicate into black 96-well plates. Plates were 
loaded into a CLARIOstar (BMG Labtech), and measure-
ments were taken every 5 min after shaking, for 72 h at 
37  °C  min (excitation and emission wavelength 440  nm 
and 510 nm respectively).
TEM
Recombinant tau fibrils were mounted on carbon-coated 
copper grids (EM Resolutions) via suspension of the grid 
on a single droplet. The grid was then stained with 1% 
uranyl acetate and imaged with a FEI Tecnai G20 electron 
microscope operating at 200 kV and an AMT camera.
Preparation of tau assemblies from brains and OHSCs
Tau was extracted from aged brains (26 weeks) from mice 
transgenic for human P301S tau using sarkosyl extrac-
tion. Tissues were homogenised for 30  s in 4 volumes 
of ice-cold H-Buffer (10 mM Tris pH 7.4, 1 mM EGTA, 
0.8  M NaCl, 10% sucrose, protease and phosphatase 
inhibitors (Halt™ Protease and Phosphatase Inhibitor 
Cocktail)) using the VelociRuptor V2 Microtube Homog-
eniser (Scientific Laboratory Supplies). The homogenates 
were spun for 20 min at 20,000× g and supernatant was 
collected. The resulting pellet was re-homogenised as 
above in 2 volumes of ice-cold H-Buffer and processed 
as above. Supernatants from both spins were combined 
and sarkosyl was added to a final concentration of 1% 
and incubated for 1 h at 37  °C. Supernatants were then 
spun at 100,000× g at 4  °C for 1  h. The resulting pellet 
was resuspended in 0.2 volumes of PBS and sonicated for 
15 s in a water-bath sonicator before storage at − 80  °C. 
For OHSCs, the same procedure was followed, except 
slices were freeze thawed 5 times in 20  μl per slice ice-
cold H-Buffer and the final pellet was resuspended in 5 μl 
per slice PBS.
Western blotting
Samples were transferred to fresh microcentrifuge tubes, 
to which appropriate volumes of 4 × NuPAGE LDS 
sample buffer (Thermo Fisher) containing 50  mM DTT 
was added and heated to 95 °C for 5 min. Samples were 
resolved using NuPAGE Bis–Tris Novex 4–12% gels 
(Life Technologies) and electroblotted to a 0.2-μm PVDF 
membrane using the Transblot Turbo Transfer System 
(Bio-Rad). Membranes were blocked with 5% milk TBS–
Tween 20 before incubation with primary antibodies at 
4  °C (Human tau HT7, MN1000, Thermofisher; CypB, 
sc-130626, Santa Cruz Biotech; Pan-tau, A0024, DAKO; 
AT100, MN1060, Thermofisher; GAPDH-HRP, Protein-
tech). Membranes were then probed with appropriate 
secondary antibodies conjugated with HRP for 1 h (Goat 
anti-mouse-HRP SA00001-1 Proteintech; Goat anti-
rabbit-HRP SA00001-2 Proteintech). Membranes were 
washed repeatedly in TBS–0.1% Tween-20 after both 
primary and secondary antibody incubation. Blots were 
incubated with Pierce Super Signal or Millipore Immo-
bilon enhanced chemiluminescence reagents for 5  min 
and visualised using a ChemiDoc system (Bio-Rad).
Dot blot
Recombinant or mouse-extracted tau fibrils were diluted 
in PBS as indicated in Additional file  1: Supplementary 
Fig.  1 and applied to 0.2  µm nitrocellulose membrane 
using the Bio-Dot microfiltration apparatus (Bio-Rad). 
The membranes were then blocked in 5% milk TBS-
Tween 20 and subsequently incubated with primary anti-
body overnight (Pan-tau, A0024, DAKO). The next day, 
the membranes were probed with goat anti-rabbit sec-
ondary antibody conjugated with Alexa488 fluorophore 
and imaged using the ChemiDoc system (Bio-Rad). The 
dot intensities were quantified with the Image Studio Lite 
software (LI-COR Biosciences) and the values for the 
recombinant fibrils were fitted to a simple linear regres-
sion curve.
Seeding assay in HEK293
The seeding assay was carried out as described previ-
ously [26]. Briefly, HEK293 P301S tau-venus cells were 
plated at 20,000 cells per well in black 96-well plates pre-
coated with poly D-lysine in 50 µL OptiMEM (Thermo 
Fisher). Tau assemblies were diluted in 50 µL OptiMEM 
(Thermo Fisher) and added to cells with 0.5  µl per well 
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Lipofectamine 2000. After 1 h, 100 µL complete DMEM 
was added to each well to stop the transfection process. 
Cells were incubated at 37  °C in an IncuCyte® S3 Live-
Cell Analysis System for 48–72 h after addition of fibrils.
Preparation and culturing of organotypic slices
Organotypic hippocampal slice cultures were prepared 
and cultured according to the protocols described pre-
viously [20, 24]. Brains from P6-P9 pups were rap-
idly removed and kept in ice-cold Slicing Medium 
(EBSS + 25  mM HEPES) on ice. All equipment was 
kept ice-cold. Brains were bisected along the midline 
and the cerebellum was removed using a sterile scalpel. 
The medial, cut surface of the brain was adhered to the 
stage of a Leica VT1200S Vibratome using cyanoacr-
ylate (Loctite Super Glue) and the vibratome stage was 
flooded with ice-cold Slicing Medium. Hemispheres were 
arranged such that the vibratome blade sliced in a rostral 
to caudal direction. Sagittal slices of 300  µm thickness 
were prepared and the hippocampus was sub-dissected 
using sterile needles. Hippocampal slices were trans-
ferred to 15 ml tubes filled with ice-cold Slicing Medium 
using sterile plastic pipettes with the ends cut off. Slices 
were then transferred onto sterile 0.4  μm pore mem-
branes (Millipore PICM0RG50) in 6-well plates pre-filled 
with 1 ml pre-warmed Culture Medium (50% MEM with 
GlutaMAX, 18% EBSS, 6% EBSS + D-Glucose, 1% Penicil-
lin–Streptomycin, 0.06% nystatin and 25% Horse Serum) 
and incubated at 37  °C in a humid atmosphere with 5% 
 CO2. Three slices were typically maintained per well. 24 h 
after plating 100% media was exchanged and thereafter a 
50% media exchange was carried out twice per week. For 
seeding experiments, tau assemblies were diluted in 1 ml 
Culture Medium and added to the underside of the mem-
brane with 100% media change. After three days, assem-
blies were removed by 100% media change. Alternatively, 
20  μl of tau assemblies diluted in Culture Medium was 
applied directly to OHSCs on the apical side.
Adeno‑associated virus
AAV1/2.hSyn-GFP particles were generated by co-
transfection of HEK293T cells with AAV2/1 (Addgene 
112862), AAV2/2 (Addgene 104963), adenovirus helper 
plasmid pAdDeltaF6 (Addgene 112867) and pAAV-hSyn-
EGFP (Addgene 50465). Virus particles were purified 
by iodixanol gradient in at T70i ultracentrifuge rotor as 
previous [41]. Viral purity was confirmed by the presence 
of three bands following SDS-PAGE and staining with 
Coomassie InstantBlue and viral titre was determined by 
quantitative PCR.
Immunofluorescence microscopy
Slices on membranes were washed with PBS and then 
fixed in 4% (w/v) paraformaldehyde for 20 min at 37 °C. 
Subsequently, membranes were rinsed 2–3 times with 
PBS and left shaking gently for 15 min to remove traces of 
paraformaldehyde before subsequent processing. Slices 
were cut from the insert using a scalpel, leaving ample 
membrane around the circumference of the slice, and 
placed with tweezers, slice side up, into 24 well plates for 
staining. Slices were permeabilised with 300 μl 0.5% (v/v) 
Triton X-100 in immunofluorescence blocking buffer (IF 
block) (3% goat serum in 1 × PBS) for 1 h at room tem-
perature and rinsed 3 times with TBS. Slices were then 
incubated with primary antibodies (MAP2, ab5392, 
Abcam; human tau HT7, MN1000, Thermofisher; pan-
tau, A0024, DAKO; phospho-tau AT8, MN1020 Ther-
mofisher; Gfap, G3893, Sigma; Iba1, ab178846, Abcam) 
diluted in IF block overnight at 4 °C, rinsed with 3 times 
with TBS, and incubated for 2 h in the dark with second-
ary antibodies, also diluted in IF block. Secondary anti-
bodies conjugated to Alexa Fluor 488, 568 or 647 were 
obtained from Thermo Fisher. Following rinsing 3 times 
with TBS, the slices were incubated with Hoechst stain 
for 10  min and rinsed 3 times with TBS. Membranes 
were placed on slides (slice side up), mounting medium 
(ProLong Diamond, Life Technologies) was added and 
a cover slip was placed on top of the slices. Images were 
captured using a Zeiss LSM780 Confocal Microscope 
with either a 20× or a 63× objective lens. Images were 
collected and stitched, where appropriate, using ZEISS 
Zen software package.
Image analysis and statistics
For tau seeding assays in HEK293 cells, aggregates were 
detected and quantified using the ComDet plugin in Fiji 
[42]. Threshold levels for detection of aggregates were 
adjusted using mock-seeded images for each experi-
ment. Levels of seeding were calculated as (number of 
aggregates)/(total cells) × 100 for individual fields. For 
slice cultures, maximum intensity Z-projections were 
interrogated for AT8 immunoreactivity by the applica-
tion of a binary threshold-based mask in ImageJ. Per-
cent area of AT8 reactivity was determined in regions of 
100 × 100 µm. GFP positive neurons upon AAV infection 
were analysed in the same way. For measures of number 
of neurons affected in hippocampal subregions, a manual 
count of cell bodies positive for AT8 immunoreactivity 
was performed. Zero values were given an arbitrary value 
of  10−5 for representation on log-scale axes. The data in 
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all graphs are represented as the mean +/− SD. Data was 
analysed via the Kruskal–Wallis test by ranks, unless it 
was determined to be normally distributed, in which case 
a one-way ANOVA was employed. All statistics were car-
ried out in GraphPad Prism Version 8.
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